1. Home
  2. VS vs IMRN Comparison

VS vs IMRN Comparison

Compare VS & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.35

Market Cap

9.3M

Sector

Technology

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.12

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VS
IMRN
Founded
2013
1994
Country
United States
Australia
Employees
5
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
9.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
VS
IMRN
Price
$1.35
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.3K
42.5K
Earning Date
04-15-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.68
52 Week High
$2.72
$2.38

Technical Indicators

Market Signals
Indicator
VS
IMRN
Relative Strength Index (RSI) 45.18 46.48
Support Level $1.17 $1.07
Resistance Level $1.78 $1.24
Average True Range (ATR) 0.13 0.10
MACD -0.02 -0.01
Stochastic Oscillator 8.93 16.63

Price Performance

Historical Comparison
VS
IMRN

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: